ATE123285T1 - Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate. - Google Patents

Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate.

Info

Publication number
ATE123285T1
ATE123285T1 AT89313218T AT89313218T ATE123285T1 AT E123285 T1 ATE123285 T1 AT E123285T1 AT 89313218 T AT89313218 T AT 89313218T AT 89313218 T AT89313218 T AT 89313218T AT E123285 T1 ATE123285 T1 AT E123285T1
Authority
AT
Austria
Prior art keywords
production
pharmaceutical preparations
preparations containing
purine compounds
pyrimidine
Prior art date
Application number
AT89313218T
Other languages
English (en)
Inventor
Lilia Marie Beauchamp
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26294743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123285(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888829571A external-priority patent/GB8829571D0/en
Priority claimed from GB898905159A external-priority patent/GB8905159D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE123285T1 publication Critical patent/ATE123285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89313218T 1988-12-19 1989-12-18 Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate. ATE123285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888829571A GB8829571D0 (en) 1988-12-19 1988-12-19 Antiviral compounds
GB898905159A GB8905159D0 (en) 1989-03-07 1989-03-07 Antiviral compounds

Publications (1)

Publication Number Publication Date
ATE123285T1 true ATE123285T1 (de) 1995-06-15

Family

ID=26294743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89313218T ATE123285T1 (de) 1988-12-19 1989-12-18 Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate.

Country Status (9)

Country Link
US (1) US5043339A (de)
EP (1) EP0375329B1 (de)
JP (1) JP2788084B2 (de)
AT (1) ATE123285T1 (de)
AU (1) AU618436B2 (de)
CA (1) CA2005815C (de)
CY (1) CY2058B1 (de)
DE (2) DE68922903T2 (de)
HK (1) HK1000142A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
KR0155168B1 (ko) * 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
USRE37979E1 (en) * 1989-09-29 2003-02-04 Mitsubishi Chemical Corporation Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
DE69126469T2 (de) * 1990-03-29 1998-01-29 Mitsubishi Chem Corp Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
DE4020481A1 (de) * 1990-06-27 1992-01-02 Hoechst Ag Verfahren zur herstellung von substituierten acyclischen nukleosiden und dabei auftretende zwischenprodukte
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5192764A (en) * 1991-05-30 1993-03-09 Research Foundation Of State Of N.Y. Pyrazinone n-oxide nucleosides and analogs thereof
EP0702682B1 (de) * 1993-06-10 2001-03-14 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
AU679763B2 (en) * 1993-06-23 1997-07-10 Merrell Pharmaceuticals Inc. Carbo-acyclic nucleoside derivatives as antiviral and antineoplastic agents
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
TW282470B (de) * 1993-11-18 1996-08-01 Ajinomoto Kk
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US6083953A (en) * 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
PE32296A1 (es) * 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
CN1064683C (zh) * 1996-01-26 2001-04-18 弗·哈夫曼-拉罗切有限公司 制备嘌呤衍生物的方法
US6040446A (en) 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
JP2001503767A (ja) * 1996-11-12 2001-03-21 メディヴィル・アクチボラグ ヌクレオシド
DE69829784T2 (de) * 1997-08-15 2006-02-16 Medivir Ab 3'-Fluorierte Guanosinderivate zur Behandlung oder Prophylaxe von HBV- oder retroviralen Infektionen
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
KR100890022B1 (ko) 2002-07-19 2009-03-25 삼성전자주식회사 액정 표시 장치 및 그 구동 방법
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
WO2005092891A2 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Preparation of esters of ganciclovir
WO2005120577A2 (en) * 2004-06-09 2005-12-22 Ramot At Tel Aviv University Ltd. Derivatives of chemotherapeutic agents with a formaldehyde releasing moeity
CA2675134A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Pterin analogs
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
WO2011064793A1 (en) 2009-11-24 2011-06-03 Matrix Laboratories Ltd Process for the preparation of amorphous valganciclovir hydrochloride
US20110207931A1 (en) * 2010-02-23 2011-08-25 Srinivas Katkam Preparation of valganciclovir and its salts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4868187A (en) * 1980-09-16 1989-09-19 Syntex (U.S.A.) Inc. Anti-viral N-substituted pyrimidines
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
HU189609B (en) * 1981-08-11 1986-07-28 The Wellcome Foundation Ltd,Us Process for production of new purin derivatives with antivirus effect and medical preparatives containing thereof as reagent
AU564576B2 (en) * 1981-09-24 1987-08-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Purine derivatives
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
DE3376326D1 (en) * 1982-10-14 1988-05-26 Wellcome Found Antiviral purine derivatives
EP0167385B1 (de) * 1984-07-03 1992-03-18 The Wellcome Foundation Limited Antiviren-Verbindungen, Behandlung und Formulierungen
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.

Also Published As

Publication number Publication date
US5043339A (en) 1991-08-27
CA2005815A1 (en) 1990-06-19
EP0375329A2 (de) 1990-06-27
AU4690989A (en) 1990-06-21
JP2788084B2 (ja) 1998-08-20
AU618436B2 (en) 1991-12-19
EP0375329A3 (de) 1991-08-14
EP0375329B1 (de) 1995-05-31
CY2058B1 (en) 1998-04-30
HK1000142A1 (en) 1997-12-24
DE10299039I1 (de) 2003-02-20
JPH02218667A (ja) 1990-08-31
DE68922903T2 (de) 1995-11-23
CA2005815C (en) 1999-08-03
DE68922903D1 (de) 1995-07-06

Similar Documents

Publication Publication Date Title
DE10299039I1 (de) Antivirale Pyrimidin- und Purinverbindungen Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Praeparte
MY103760A (en) Therapeutic nucleosides
EP0349242A3 (de) Therapeutische Nuleoside
CA2033044A1 (en) 6-substituted purine carbocyclic nucleosides
BR9914097A (pt) Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto
NO2007016I2 (no) Nelarabin eller et farmasoytisk akseptabelt salt derav ( nelarabin=9-(beta-D-arabinofuranosyl-2-amino-6-metoksy-9H-purin)
DE3689976D1 (de) Therapeutische Nucleoside und deren Herstellung.
MY102248A (en) Derivatives of 9-(2-hydroxyethoxymethyl) guanine
IE892654L (en) Therapeutic nucleosides
EP0346108A3 (de) Anti-infektiöse Nukleoside
DE69033252D1 (de) Therapeutische nukleoside
ZA898926B (en) Antiviral compounds
GEP19970908B (en) Esters of 9-(2-hydroxyethoxymethyl)guanine having antiviral properties
RU93004467A (ru) Замещенные пуриновые арабинозы, их применение, фармацевтическая композиция